UK markets closed
  • FTSE 100

    -18.39 (-0.22%)
  • FTSE 250

    -72.94 (-0.35%)
  • AIM

    +1.52 (+0.19%)

    +0.0023 (+0.20%)

    +0.0035 (+0.28%)
  • Bitcoin GBP

    +47.98 (+0.09%)
  • CMC Crypto 200

    -2.51 (-0.18%)
  • S&P 500

    +6.17 (+0.12%)
  • DOW

    +134.21 (+0.34%)

    +0.77 (+0.97%)

    +34.30 (+1.44%)
  • NIKKEI 225

    -132.88 (-0.34%)

    +177.08 (+0.91%)
  • DAX

    -34.39 (-0.18%)
  • CAC 40

    -20.99 (-0.26%)

Plasmid DNA Manufacturing Global Market Report 2023: Inorganic Growth Strategies Continue to Bolster Sector Expansion

Company Logo
Company Logo

Global Plasmid DNA Manufacturing Market

Global Plasmid DNA Manufacturing Market
Global Plasmid DNA Manufacturing Market

Dublin, Feb. 28, 2023 (GLOBE NEWSWIRE) -- The "Plasmid DNA Manufacturing Market, By Product Type, By Grade, By Application, By Manufacturing Type, By Development Phase, By Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to's offering.

Circular double-stranded DNA present in the cytoplasm of a bacteria that replicate independently from the bacterial chromosome is called a plasmid DNA. Plasmids are small extra chromosomal DNA molecules within cells that are physically separated from the chromosomal DNA and capable of independent replication. They are most commonly found as small circular double-stranded DNA molecules in bacteria. However, plasmids can be present in archaea and eukaryotes.

Market Dynamics:

Demand for innovation in existing manufacturing technologies, in order to meet the requirement of appropriate products and its volume is expected to provide immense growth opportunities for key players in the market. For instance, in March 2021, Evolugate, LLC, a Gainesville-based biotech company, has demonstrated that its proprietary technology can be used to improve the throughput of plasmid DNA manufacturing.

The increasing inorganic strategies such as acquisition by key players in the market to expand product portfolios is expected to drive the market growth over the forecast period. For instance, In January 2022, Aldevron announced the acquisition of Nature Technology Corporation (NTC), a developer of innovative and proprietary plasmid constructs and manufacturing solutions that are used in the field of cell and gene therapy. NTC's nucleic acid-based technologies include Nanoplasmid, a proprietary vector construct that improves the safety and performance of plasmids and biologics.

Key features of the study:

  • This report provides in-depth analysis of the global plasmid DNA manufacturing market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year

  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

  • It profiles key players in the global plasmid DNA manufacturing market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies Key companies covered as a part of this study include Cobra Biologics and Pharmaceutical Services (Charles River Laboratories), VGXI, Inc., Aldevron (Danaher), Kaneka Corporation, Nature Technology, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, LakePharma, Inc., MeiraGTx Limited, Eurofins Genomics, Vigene Biosciences, Luminous BioSciences (LBS), LLC, GenScript, GENEWIZ, Creative Biogene, Akron Biotech, Biomay, JAFRAL Ltd., WuXi Biologics, GeneImmune Biotechnology Corp., Lonza, Greenpak Biotech Ltd., Luina Bio (AcuraBio), Ajinomoto Bio-Pharma, Synbio Technologies, Genopis Inc., Altogen Biosystems, Puresyn, Inc., Cepham Life Sciences, Catalent, Inc., Biomiga, Waisman Biomanufacturing

  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

  • The global plasmid DNA manufacturing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global plasmid DNA manufacturing market

Detailed Segmentation:
Global Plasmid DNA Manufacturing Market, By Product Type:

  • Viral Vectors

  • Retroviral

  • Adenoviral

  • Lentiviral

  • Adeno Associates

  • Others

  • Plasmid DNA

  • mRNA

  • Others

  • Non-viral

  • Lipid/Polymer

  • Electroporation

  • Nanoparticles

  • Others

Global Plasmid DNA Manufacturing Market, By Grade:

  • GMP Grade

  • R&D Grade

  • Clinical Grade

Global Plasmid DNA Manufacturing Market By Application:

  • DNA Vaccines

  • Gene Therapy

  • Immunotherapy

  • RNA Vaccines

  • Others

Global Plasmid DNA Manufacturing Market By Manufacturing Type:

  • Outsourcing

  • In-house Manufacturing

Global Plasmid DNA Manufacturing Market By Development Phase:

  • Pre-Clinical Therapeutics

  • Clinical Therapeutics

  • Marketed Therapeutics

Global Plasmid DNA Manufacturing Market, By Region:

  • North America

  • U.S.

  • Canada

  • Latin America

  • Brazil

  • Mexico

  • Argentina

  • Rest of Latin America

  • Europe

  • Germany

  • U.K.

  • France

  • Italy

  • Spain

  • Russia

  • Rest of Europe

  • Asia Pacific

  • India

  • China

  • Japan

  • Australia


  • South Korea

  • Rest of Middle East

  • Middle East

  • GCC

  • Isreal

  • Japan

  • Africa

  • South Africa

  • Central Africa

  • North Africa

Report Attribute


No. of Pages


Forecast Period

2022 - 2030

Estimated Market Value (USD) in 2022

$735.67 Million

Forecasted Market Value (USD) by 2030

$3733.5 Million

Compound Annual Growth Rate


Regions Covered


A selection of companies mentioned in this report includes

  • Cobra Biologics and Pharmaceutical Services (Charles River Laboratories)

  • VGXI, Inc.

  • Aldevron (Danaher)

  • Kaneka Corporation

  • Nature Technology

  • PlasmidFactory GmbH & Co. KG

  • Cell and Gene Therapy Catapult

  • LakePharma, Inc.

  • MeiraGTx Limited

  • Eurofins Genomics

  • Vigene Biosciences

  • Luminous BioSciences (LBS), LLC

  • GenScript


  • Creative Biogene

  • Akron Biotech

  • Biomay

  • JAFRAL Ltd.

  • WuXi Biologics

  • GeneImmune Biotechnology Corp.

  • Lonza

  • Greenpak Biotech Ltd.

  • Luina Bio (AcuraBio)

  • Ajinomoto Bio-Pharma,

  • Synbio Technologies, Genopis Inc.

  • Altogen Biosystems, Puresyn, Inc.

  • Cepham Life Sciences, Catalent, Inc.

  • Biomiga

  • Waisman Biomanufacturing

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


CONTACT: CONTACT: Laura Wood,Senior Press Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900